Atara biotherapeutics submits tabelecleucel (tab-cel®) biologics license application for treatment of epstein-barr virus positive post-transplant lymphoproliferative disease with u.s. fda

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that atara has submitted a biologics license application (bla) to the u.s. food and drug administration (fda) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie.
ATRA Ratings Summary
ATRA Quant Ranking